AvKARE, Inc.
AvKARE, Inc. (United States) has no DMF, CEP or site registration linked in our records. 50 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “AvKARE, Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/avkare-inc
Overview
AvKARE, Inc. is a leading provider in the pharmaceutical distribution sector, specializing in servicing the healthcare needs for hospitals, healthcare facilities, and the government. As a private company, AvKARE has established a reputation for quality and reliability in the distribution of pharmaceuticals.
Core services & business areas
Therapeutic areas
FDA compliance signals
50 FDA enforcement records linked to this company.
- recall — Class II2026-03-04
Failed Dissolution Specifications: This recall has been initiated due to an Out of Specification finding in dissolution.
- recall — Class II2026-01-14
Out of specification for dissolution.
- recall — Class II2025-10-15
Failed Content Uniformity Specifications
- recall — Class II2025-09-17
Presence of a foreign substance.
- recall — Class II2025-09-17
Presence of a foreign substance.
- recall — Class III2025-07-09
Failed Impurity/Degradation Specifications
- recall — Class III2025-07-09
Failed Impurity/Degradation Specifications
- recall — Class II2025-06-18
Failed Dissolution Specifications
- recall — Class II2025-06-18
Presence of Foreign Tablets/Capsules: manufacturer recalled because one tadalafil 5mg tablet was found in 500 count bottle of Celecoxib 200 mg capsules
- recall — Class II2025-02-26
Subpotent Drug: Out of Specification (OOS) result for De hydro Impurity (0.654%) for 18 M Stability sample and low assay 94.9% (specification of NLT 95.0% NMT 105%)
- recall — Class II2025-02-19
Out of Specification for Dissolution
- recall — Class II2025-01-08
Failed Dissolution Specifications
- recall — Class III2025-01-08
LABELING: LABEL MIX-UP
- recall — Class III2025-01-08
LABELING: LABEL MIX-UP
- recall — Class II2024-12-11
CGMP deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Cinacalcet above acceptable intake limit.
- recall — Class II2024-12-11
CGMP deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Cinacalcet above acceptable intake limit.
- recall — Class II2024-12-11
CGMP deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Cinacalcet above acceptable intake limit.
- recall — Class II2024-12-11
Labeling: Label Mix-Up
- recall — Class II2024-12-11
Labeling: Label Mix-Up
- recall — Class I2024-04-24
Microbial contamination of a non-sterile product: potential Bacillus cereus contamination.
- recall — Class II2023-09-13
Cases of Sodium Fluoride 1.1% Prescription Dental Toothpaste may contain cartons labeled as Capsaicin Cream 0.025% but contain correctly labeled tubes of Sodium Fluoride 1.1% Prescription Dental Toothpaste
- recall — Class II2023-09-13
Product mix-up: Cartons labeled Capsaicin Cream 0.025% may contain tubes of Sodium Fluoride 1.1% Prescription Dental Toothpaste
- recall — Class III2023-06-21
Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.
- recall — Class II2023-01-04
Failed impurities/degradation specifications: Out of specification for unknown impurities.
- 4832022-11-02
Procedures not in writing, fully followed
- recall — Class III2022-08-17
Labeling: Label Error on Declared Strength
- recall — Class III2021-06-23
Failed Impurities Specification: Out of specification when measuring the impurity degradant D level.
- recall — Class I2020-12-23
Product mix-up: Bottles of sildenafil and trazodone were inadvertently packaged together during bottling at a 3rd party facility.
- recall — Class II2020-12-23
Product mix-up: Bottles of sildenafil and trazodone were inadvertently packaged together during bottling at a 3rd party facility.
- recall — Class II2020-11-18
Failed Dissolution Specifications
- recall — Class II2020-06-24
CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
- recall — Class II2020-06-24
CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
- recall — Class III2020-06-10
Presence of Foreign Substance consistent with granules from desiccant packs used during storage
- recall — Class II2020-01-22
Failed Impurities/Degradation Specifications: High out of specification results for related compounds.
- recall — Class II2019-12-04
CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API
- recall — Class II2019-12-04
CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API
- recall — Class II2019-11-06
CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API
- recall — Class II2019-11-06
CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API
- recall — Class II2019-09-18
Failed Stability Specifications.
- recall — Class II2019-05-08
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 0.96 parts per million.
- recall — Class II2019-05-08
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 0.96 parts per million.
- recall — Class III2019-04-17
Failed Impurities/Degradation Specifications; 18 month long term stability study (manufacturer)
- recall — Class II2019-03-27
CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identified
- recall — Class II2019-03-27
CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identified
- recall — Class II2019-03-27
CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identified
- recall — Class III2019-03-20
Failed Dissolution Specifications
- recall — Class II2018-12-05
Microbial Contamination of Non-Sterile Product: Presence of Pseudomonas aeruginosa in product
- recall — Class II2018-09-12
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
- recall — Class II2018-09-12
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
- recall — Class II2018-09-12
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Is this AvKARE, Inc.?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Related companies
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.